{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:47:50Z","timestamp":1790092070639,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.cgh.2006.05.020","type":"journal-article","created":{"date-parts":[[2006,7,17]],"date-time":"2006-07-17T21:28:35Z","timestamp":1153171715000},"page":"1017-1024","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Risks and Benefits of Infliximab for the Treatment of Crohn\u2019s Disease"],"prefix":"10.1016","volume":"4","author":[{"given":"Corey A.","family":"Siegel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua R.","family":"Korzenik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Scott","family":"Gazelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2006.05.020_bib1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMra020831","article-title":"Inflammatory bowel disease","volume":"347","author":"Podolsky","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2006.05.020_bib2","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.4049\/jimmunol.159.12.6276","article-title":"A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn\u2019s disease","volume":"159","author":"Plevy","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.cgh.2006.05.020_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/cyto.1995.1003","article-title":"The mouse\/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo","volume":"7","author":"Siegel","year":"1995","journal-title":"Cytokine"},{"key":"10.1016\/j.cgh.2006.05.020_bib4","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2006.05.020_bib5","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2006.05.020_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn\u2019s disease","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2006.05.020_bib7","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2006.05.020_bib8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn\u2019s disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2006.05.020_bib9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/gut.2003.018515","article-title":"Infliximab in inflammatory bowel disease","volume":"53","author":"Ljung","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2006.05.020_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000080075","article-title":"Safety aspects of infliximab in inflammatory bowel disease patients","volume":"70","author":"Seiderer","year":"2004","journal-title":"Digestion"},{"key":"10.1016\/j.cgh.2006.05.020_bib11","unstructured":"SEER. Surveillance, Epidemiology, and End Results Database. Available at: http:\/\/seer.cancer.gov\/."},{"key":"10.1016\/j.cgh.2006.05.020_bib12","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/gast.2001.28703","article-title":"Inflammatory bowel disease is not associated with an increased risk of lymphoma","volume":"121","author":"Lewis","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2006.05.020_bib13","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","article-title":"Cancer risk in patients with inflammatory bowel disease","volume":"91","author":"Bernstein","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.cgh.2006.05.020_bib14","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/1097-0142(19910401)67:7<2015::AID-CNCR2820670731>3.0.CO;2-R","article-title":"Extracolonic malignancies in inflammatory bowel disease","volume":"67","author":"Ekbom","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.cgh.2006.05.020_bib15","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1002\/1097-0142(19851215)56:12<2914::AID-CNCR2820561232>3.0.CO;2-J","article-title":"Extraintestinal cancers in inflammatory bowel disease","volume":"56","author":"Greenstein","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.cgh.2006.05.020_bib16","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1111\/j.1572-0241.2000.02316.x","article-title":"Risk of lymphoma in inflammatory bowel disease","volume":"95","author":"Loftus","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2006.05.020_bib17","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/0016-5085(94)90807-9","article-title":"Crohn\u2019s disease and cancer","volume":"107","author":"Persson","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2006.05.020_bib18","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0016-5085(00)70353-2","article-title":"Azathioprine for maintenance of remission in Crohn\u2019s disease","volume":"118","author":"Lewis","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2006.05.020_bib19","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0140-6736(94)92150-4","article-title":"Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease","volume":"343","author":"Connell","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2006.05.020_bib20","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/gut.47.4.514","article-title":"Increased incidence of non-Hodgkin\u2019s lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low","volume":"47","author":"Farrell","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2006.05.020_bib21","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-111-8-641","article-title":"6-Mercaptopurine in the management of inflammatory bowel disease","volume":"111","author":"Present","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2006.05.020_bib22","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2006.05.020_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0016-5085(99)70549-4","article-title":"Clinical course and costs of care for Crohn\u2019s disease","volume":"117","author":"Silverstein","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2006.05.020_bib24","first-page":"399","article-title":"Mortality in Crohn\u2019s disease","volume":"71","author":"Andrews","year":"1989","journal-title":"Q J Med"},{"key":"10.1016\/j.cgh.2006.05.020_bib25","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/gut.31.12.1387","article-title":"Mortality and causes of death in Crohn\u2019s disease","volume":"31","author":"Weterman","year":"1990","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2006.05.020_bib26","doi-asserted-by":"crossref","first-page":"132","DOI":"10.7326\/0003-4819-123-2-199507150-00009","article-title":"Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis","volume":"123","author":"Pearson","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2006.05.020_bib27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00054725-199712000-00004","article-title":"An evaluation of utility measurements in Crohn\u2019s disease","volume":"3","author":"Gregor","year":"1997","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2006.05.020_bib28","first-page":"463","article-title":"Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin\u2019s lymphoma (NHL)","volume":"16","author":"Uyl-de Groot","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cgh.2006.05.020_bib29","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1007\/s10350-004-0725-6","article-title":"Azathioprine or ileocolic resection for steroid-dependent terminal ileal Crohn\u2019s disease?","volume":"47","author":"Kennedy","year":"2004","journal-title":"a Markov analysis. Dis Colon Rectum"},{"key":"10.1016\/j.cgh.2006.05.020_bib30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3233\/BD-1998-103-405","article-title":"Screening mammography for women in their forties","volume":"10","author":"Berry","year":"1998","journal-title":"Breast Dis"},{"key":"10.1016\/j.cgh.2006.05.020_bib31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF02599951","article-title":"A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction","volume":"10","author":"Kalish","year":"1995","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.cgh.2006.05.020_bib32","first-page":"A-580","article-title":"Safety of infliximab and other Crohn\u2019s disease therapies","volume":"128","author":"Lichtenstein","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2006.05.020_bib33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease","volume":"121","author":"Faubion","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2006.05.020_bib34","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn\u2019s disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2006.05.020_bib35","unstructured":"US life 1997 tables 1997: national vital statistics report. Atlanta, GA: Center for Health Statistics, CDC."}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356506004897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356506004897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:58:23Z","timestamp":1761541103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356506004897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S1542356506004897"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2006.05.020","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risks and Benefits of Infliximab for the Treatment of Crohn\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2006.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2006.05.033","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2006.05.023","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 American Gastroenterological Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}